Integrative study of EZH2 mutational status, copy number, protein expression and H3K27 trimethylation in AML/MDS patients.
Julia StomperRuth MeierTobias MaDietmar PfeiferGabriele IhorstNadja Blagitko-DorfsGabriele GreveDennis ZimmerUwe PlatzbeckerAnne HagemeijerIngrid Schmitt-GraeffMichael LübbertPublished in: Clinical epigenetics (2021)
Perturbations of EZH2 activity in AML/MDS occur on different, genetic and non-genetic levels. Both low EZH2 protein expression and, by trend, EZH2 gene mutations predicted inferior overall survival of AML patients receiving standard chemotherapy.
Keyphrases
- copy number
- acute myeloid leukemia
- mitochondrial dna
- genome wide
- long noncoding rna
- long non coding rna
- end stage renal disease
- ejection fraction
- allogeneic hematopoietic stem cell transplantation
- newly diagnosed
- chronic kidney disease
- dna methylation
- peritoneal dialysis
- patient reported outcomes
- gene expression
- free survival
- locally advanced
- patient reported